The number of clinical trials related to genetically-modified organisms and recombinant DNA will increase exponentially in the next decade. This article describes and compares the European, United States, and Canadian regulatory requirements for conducting clinical trials related to genetically-modified organisms and recombinant DNA. In Europe, the additional regulatory requirements include submissions and approvals from the local and national genetically-modified organisms safety committees, and the gene therapy committee (if applicable). If the genetically-modified organism is imported from another country, an “importer” certification is also required. In the United States, the additional regulatory requirements include review/approval by the institutional biosafety committee and the Recombinant DNA Advisory Committee. For gene therapy, additional information is required by the Food and Drug Administration. In Canada, review by the institutional biosafety committee (for biological hazards) and Canadian Institutes of Health Research (for research it funds) is required.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Guidelines for Research Involving Recombinant DNA Molecules. Bethesda, MD: National Institutes of Health; April 1988.
“Availability for Public Disclosure and Submission to FDA of Certain Data and Information Related to Human Gene Therapy of Xenotransplantation.” Proposed rule. Federal Register. January 18, 2001, Vol. 66, No 12.
United States Food and Drug Administration. “Dear Gene Therapy IND or Master File Sponsor” letter. Rockville, MD: United States Food and Drug Administration; March 6, 2000.
Clairmont C, Lee K, Ittensohn M, Pike J, Bermudes D, Margitich D, Kuhlman S, Li Z, Lu X, Mao J, King I, Zheng LM. Pre-clinical toxicology by VNP20009, a genetically modified Salmonella typh-imurium for treatment of solid tumors. American Association for Cancer Research, March 1998.
Clairmont C, Bermudes D, Low KB, Pawelek J, Pike J, Ittensohn M, Li Z, Luo X, Margitich D, Lee K, Zheng LM, King I. VNP20009, a genetically modified Salmonella typhimurium: anti-tumor efficacy, toxicology and bio-distribution in pre-clinical models. Presented at Molecular Targets and Cancer Therapeutics, American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer International Conference, Washington, DC, (501), 1999.
Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infectious Diseases. 2000;181:1996–2002.
Doyle TW, Almassian B, Bahramian B, Bermudes D, Clairmont C, Ittenson M, King I, Krishna G, Lee K, et al. TAPET—Bacterial vectors for the delivery of peptides and proteins to solid tumors. American Association for Cancer Research, March 1999.
Lee KC, Zheng LM, Luo X, Clairmont C, Fischer J, Margitich D, Turnier J, Almassian B, Bermudes D, King I. Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int J Toxicology. 2000;19:19–25.
Lee KC, Zheng LM, Luo X, Clairmont C, Fischer J, Margitich D, Almassian B, Bermudes D, King I. Comparative Evaluation of the Acute Toxic Effects in Monkeys, Pigs and Mice of a Genetically-Engineered Salmonella Strain (VNP20009) Being Developed as an Antitumor Agent. Society of Toxicology, March 2001.
Lee KC, Zheng LM, Margitich D, Almassian B, King I. Evaluation of the Acute and Subchronic Toxic Effects in Monkeys, Rats and Mice of Genetically Engineered, and E. coli Cytosine Deaminase Gene Incorporated, Salmonella Strain (TAPET-CD), Being Developed as an Antitumor Agent. Int J Toxicology. 2001;20.
Li Z, Lang W, Runyan JD, Luo X, Clairmont C, Shen S-Y, Bermudes D, Lin S, Chen P, Trailsmith MD, King I, Zheng LM. Tissue distribution and in vivo expression of cytosine deaminase by TAPET-CD, a genetically engineered strain of Salmonella typhimurium as an anti-tumor vector. American Association for Cancer Research, March 2001.
Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Lou X, Miller SI, Zheng LM, King I, Pawelek J, Bermudes D. Lipid A mutant Salmonella with suppressed virulence and TNF∝ induction retain tumor-targeting in vivo. Nature Biotech. 1999;17:37–41.
Low KB, Ittensohn M, Lin S, Clairmont C, Luo X, Zheng LM, King I, Pawelek JM, Bermudes D. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors. Proceedings of the American Association of Cancer Research. 1999;40:87 (Abstract 581).
Mier J, Olencki T, Atkins M, Sznol M, MacDonald S, Mao J, Almassian B, Lee K, Akella U, Weiss P, Bukowski R. Phase 1 trial of a live, attenuated Salmonella typhimurium (VNP20009) administered by direct intra-tumoral (IT) injection. Proceedings of the American Society of Clinical Oncology. 2001; 20:261a (abstract).
Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Tes. 1997;57:4537–4544.
About this article
Cite this article
Lee, K.C. Comparison of Additional Regulatory Requirements for Conducting Clinical Trials on Genetically-Modified Microorganisms and Recombinant DNA in Europe, the United States, and Canada. Ther Innov Regul Sci 36, 379–386 (2002) doi:10.1177/009286150203600217
- Genetically-modified organisms
- Clinical trials
- United States